Robert Wessman acquired 320,000 shares of Alvotech at ISK 1,255 each, as reported to the CSSF.
Quiver AI Summary
A recent filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) reveals that Robert Wessman, the Chairman and CEO of Alvotech, has acquired 320,000 shares of the company at a price of ISK 1,255 per share during the market opening. This transaction involves both the company's management and closely associated individuals.
Potential Positives
- Announcement of a significant acquisition of 320,000 shares by Robert Wessman, Chairman and CEO, indicating strong personal investment in the company.
- The purchase price of ISK 1,255 per share may suggest confidence in Alvotech’s future performance and stability.
Potential Negatives
- Announcement of the acquisition of shares by the CEO may raise concerns about potential conflicts of interest or lack of independence in corporate governance.
- The acquisition at a specific price could prompt scrutiny regarding whether it reflects the true market value and may indicate volatility in stock value.
- The filing with a regulatory body could suggest that management needed to disclose transactions due to potential insider trading concerns.
FAQ
What recent transaction did Robert Wessman announce?
Robert Wessman announced the acquisition of 320,000 shares in Alvotech at ISK 1,255 per share.
Who is Robert Wessman?
Robert Wessman is the Chairman and CEO of Alvotech.
What regulatory body was notified about the acquisition?
The acquisition was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF).
When was the acquisition of Alvotech shares made?
The acquisition was announced at the market opening.
How many shares did Robert Wessman acquire in Alvotech?
Robert Wessman acquired 320,000 shares in Alvotech.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 29 institutional investors add shares of $ALVO stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OAKTREE CAPITAL MANAGEMENT LP removed 606,322 shares (-23.9%) from their portfolio in Q4 2024, for an estimated $8,021,640
- POINTSTATE CAPITAL LP added 484,826 shares (+64.1%) to their portfolio in Q4 2024, for an estimated $6,414,247
- LEGAL & GENERAL GROUP PLC removed 420,869 shares (-42.2%) from their portfolio in Q4 2024, for an estimated $5,568,096
- SCULPTOR CAPITAL LP removed 338,928 shares (-35.9%) from their portfolio in Q4 2024, for an estimated $4,484,017
- MORGAN STANLEY removed 257,272 shares (-14.8%) from their portfolio in Q4 2024, for an estimated $3,403,708
- MILLENNIUM MANAGEMENT LLC removed 107,172 shares (-84.7%) from their portfolio in Q4 2024, for an estimated $1,417,885
- EXOME ASSET MANAGEMENT LLC added 90,100 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,192,023
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition at the market opening of 320,000 shares in Alvotech at ISK 1,255 per share, by Robert Wessman, Chairman and CEO.
